In Multiple Sclerosis, There’s More to MRI Than Meets the Eye
May 30, 2024 – Katherine Wandersee Conferences : Consortium of Multiple Sclerosis Centers Annual Meeting (CMSC) CMSC Kurtzke Lecturer Darin…
Dark rim on MS lesions seen with standard MRI may mark activity
Possible way of spotting in clinic rim lesions known to drive progression By Marisa Wexler, MS on 02/26/2024 An imaging…
Stuart Schlossman
The MS Views and News Learning Channel, Presents: THE 2023 MS SYMPOSIUM – watch these educational videos with MS Neurologists Boster, Rosenthal, Steingo and more
PLAYING 2023 MS Symposium (Part 1 of 5) – LIVING WELL with MS, Pain Management, Biomarkers and More 40:26…
Stuart Schlossman
Understanding more about MS relapse, MRI’s and Biomarkers for Multiple Sclerosis
Click to Subscribe for the MS Beacon eNewsletter, resources and MS education Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
Octave Presents Data from Nine Company and Partner Abstracts at ACTRIMS Forum 2023 on MSDA and more
Real-world data sets show components of value-based care, use of Octave’s Multiple Sclerosis Disease Activity test and deep scan biomarker…
Stuart Schlossman
Gadolinium-based contrast agent exposures and physical and cognitive disability in multiple sclerosis
Kunio Nakamura 1, Marisa P McGinley 2, Stephen E Jones 3, Mark J Lowe 3, Jeffrey A Cohen 2, Paul M Ruggieri 3, Daniel Ontaneda 2 Affiliations expand PMID: 36181666 DOI: 10.1111/jon.13057 Abstract Background and…
Stuart Schlossman
Guerbet Announces FDA Approval of Elucirem (Gadopiclenol) for Use in Contrast-enhanced MRI
Guerbet, a global medical imaging company, has announced that the U.S. Food and Drug Administration (FDA) after priority review, approved…
Stuart Schlossman
How MS progresses over time / The Expanded Disability Status Scale and what this means
Most people with MS experience two stages of disease. The first stage is relapsing-remitting MS (RRMS), which is characterized by episodes of…
Stuart Schlossman
Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers – PubMed
Monica Margoni 1 2, Paolo Preziosa 1 3, Paola Tortorella 4, Massimo Filippi 1 3 5 6 7, Maria A Rocca 8 9 10 Affiliations expand PMID: 35668317 DOI: 10.1007/s13311-022-01252-5 Abstract Multiple sclerosis (MS) is a chronic inflammatory, demyelinating,…
Stuart Schlossman
Myelin Repair, Progressive MS, Exercise, and Other Research News
October 22, 2021 Myelin repair strategies, progressive MS, exercise, and other promising avenues took center stage at the virtual European…
Stuart Schlossman
